Novo Nordisk (NVO, Financial) and Eli Lilly (LLY, Financial) are making headlines again—this time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.
Researchers at Washington University in St. Louis examined 215,000 U.S. military veterans with diabetes, comparing those using GLP-1 drugs with those on older treatments. The findings show reduced risks for 42 conditions, including psychotic disorders, seizures, and neurocognitive diseases like Alzheimer's and dementia. However, the study also flags higher risks for kidney issues, pancreatitis, and gastrointestinal conditions among GLP-1 users.
These findings emerge as the Biden administration moves forward with Medicare price negotiations for Ozempic and Wegovy. Meanwhile, Bristol-Myers Squibb (BMY) sees potential in its schizophrenia drug, Cobenfy, as a future Alzheimer's treatment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。